Author:
Takahashi Takeshi,Usuki Kensuke,Matsue Kosei,Ohno Hitoshi,Sakura Toru,Imanaka Ryota,Murakami Masato,Ohwada Shoichi,Takagi Taiga,Sakajiri Sakura
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:926–57.
2. Niino M, Matsuda T. Type distribution of myeloid leukemia from Cancer Incidence in Five Continents vol. X. Jpn J Clin Oncol. 2016;46:394.
3. Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, et al. Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. Int J Hematol. 2010;91:276–83.
4. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074–80.
5. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532–42.